Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon/β1a or glatiramer acetate compared with untreated patients

Multiple Sclerosis

Volumn 9, Issue 5, 2003, Pages 440-445

  Jansson, A ^a   Ernerudh, J ^a   Kvarnstrom M ^a   Ekerfelt, C ^a   Vrethem, Magnus ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Elispot; Glatiramer acetate; Interferon ; Multiple sclerosis; Myelin basic protein (MBP); Myelin oligodendrocyte glycoprotein (MOG)

Indexed keywords

BETA1A INTERFERON; CYTOKINE; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN 14 39; MYELIN OLIGODENDROCYTE GLYCOPROTEIN 63 87; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; CYTOKINES; FEMALE; HUMANS; IMMUNOASSAY; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-5; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; PEPTIDES;

EID: 0142060313     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms951oa     Document Type: Article

References (26)

1. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-21.
2. Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: An open-label 2-year follow-up. J Neurol Sci 2002; 197: 51-55.
3. Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002; 58: S10-22.
4. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58: S3-9.
5. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T et al. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000; 97: 7452-57.
6. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-708.
7. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000; 85: 9-18; quiz 18, 21.
8. Paludan SR. Interleukin-4 and interferon-gamma: The quintessence of a mutual antagonistic relationship. Scand J Immunol 1998; 48: 459-68.
9. Dahle C, Ekerfelt C, Vrethem M, Samuelsson M, Ernerudh J. T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barre syndrome. J Neurol Sci 1997; 153: 54-60.
10. Ekerfelt C, Matthiesen L, Berg G, Ernerudh J. Paternal leukocytes selectively increase secretion of IL-4 in peripheral blood during normal pregnancies: Demonstrated by a novel one-way MLC measuring cytokine secretion. Am J Reprod Immunol 1997; 38: 320-26.
11. Matthiesen L, Ekerfelt C, Berg G, Ernerudh J. Increased numbers of circulating interferon-gamma- and interleukin-4-secreting cells during normal pregnancy. Am J Reprod Immunol 1998; 39: 362-67.
12. Ekerfelt C, Ernerudh J, Jenmalm MC. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: Comparison of ELISPOT, a novel ELISA and real-time RT-PCR. J Immunol Methods 2002; 260: 55-67.
13. Wensky A, Marcondes MC, Lafaille JJ. The role of IFN-gamma in the production of Th2 subpopulations: Implications for variable Th2-mediated pathologies in autoimmunity. J Immunol 2001; 167: 3074-81.
14. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-42.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
16. Wallström E, Khademi M, Andersson M, Weissert R, Linington C, Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur J Immunol 1998; 28: 3329-35.
17. Czerkinsky CC, Tarkowski A, Nilsson LA, Ouchterlony O, Nygren H, Gretzer C. Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods 1984; 72: 489-96.
18. Ekerfelt C, Ernerudh J, Bunikis J, Vrethem M, Aagesen J, Roberg M et al. Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: Secretion of IFN-gamma predominates over IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes. J Neuroimmunol 1997; 79: 155-62.
19. Bakhiet M, Ozenci V, Withagen C, Mustafa M, Fredricksson S, Link H. A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis. Clin Diagn Lab Immunol 1999; 6: 415-19.
20. Khademi M, Wallström E, Andersson M, Piehl F, DiMarco R, Olsson T. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis. J Neuroimmunol 2000; 103: 202-10.
21. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001; 7: 209-19.
22. Wiesemann E, Sonmez D, Heidenreich F, Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J Neuroimmunol 2002; 123: 160-69.
23. Özenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisäkk P, Fredriksson S et al. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand J Immunol 1999; 49: 554-61.
24. Özenci V, Kouwenhoven M, Press R, Link H, Huang YM. IL-12 elispot assays to detect and enumerate IL-12 secreting cells. Cytokine 2000; 12: 1218-24.
25. Özenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredriksson S, Link H. Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000; 108: 236-43.
26. Andersson M, Khademi M, Wallström E, Olsson T. Cytokine profile in interferon-beta treated multiple sclerosis patients: Reduction of interleukin-10 mRNA expressing cells in peripheral blood. Eur J Neurol 1997; 4: 567-71.